SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) Cash flow
Market cap
¥45.2B
P/E ratio
12.9x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 1,392 | 1,592 | 1,546 | 1,473 | 1,362 | 1,229 | 1,188 | 1,177 | 1,544 | 1,774 | 2,497 | 3,318 |
| Cash from operations | -2,156 | -3,340 | -850 | 1,344 | 2,893 | 3,018 | 4,747 | 5,953 | 4,004 | 2,107 | 7,035 | 8,327 |
| Capital expenditures | -1,408 | -1,780 | -790 | -1,013 | -1,068 | -1,147 | -1,067 | -1,543 | -4,840 | -8,583 | -10,854 | -5,174 |
| Cash from investing | -1,093 | 1,286 | -314 | 838 | 435 | -1,455 | -269 | -4,269 | -5,931 | -6,908 | -11,691 | -6,791 |
| Payments for dividends | -0 | - | - | - | - | -124 | -206 | -827 | -2,484 | -2,072 | -2,100 | -2,084 |
| Repurchases of common stock | -0 | - | - | - | - | - | - | - | - | - | -0 | -0 |
| Proceeds from issuance of term debt, net | 4,771 | 6,738 | 5,821 | 850 | 510 | 9,060 | 4,540 | - | 10,300 | 17,700 | 14,000 | 10,000 |
| Repayments of term debt | -6,708 | -6,650 | -6,658 | -5,843 | -4,708 | -4,167 | -4,598 | -3,492 | -5,468 | -6,230 | -8,826 | -9,458 |
| Cash from financing | 507 | -282 | 3,815 | -4,224 | -3,502 | -1,450 | -2,471 | -4,912 | 6,266 | 5,319 | 5,914 | 4,514 |